Barriers to MASLD Management in Europe: Findings From a Multidisciplinary HCP-survey
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 675
- 试验地点
- 1
- 主要终点
- Unaided awareness
研究概览
简要总结
The purpose of this study is to better understand the main barriers to earlier diagnosis and better management of MASLD/MASH patients and to understand the key barriers to adoption of guidelines.
This study is a cross-sectional design, conducted across 5 countries in Europe- France, Germany, Spain, United Kingdom (UK), Italy. Study participants, Hepatologists and other metabolically focused healthcare providers (HCPs), will be recruited to complete a 15 minute self-administered online survey.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Cross Sectional
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •For Hepatologists:
- •Informed consent obtained before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol).
- •Male or female, age above or equal to 18 years at the time of signing informed consent.
- •Is a physician
- •Lives in UK, France, Germany, Italy or Spain
- •Primary medical specialty is:
- •5.a. Hepatology or 5.b. Gastroenterology or Internal Medicine with a subspecialty in Hepatology
- •In practice at least 3 years
- •Spends at least 50 percent of their time in an office/clinic setting
- •Spends at least 60 percent of their time in direct patient care
- •Sees at least 15 patients/month with MASH/MASLD
- •For Metabolically-Focused HCPs (Endocrinologist/General Physician/Family Physician/Internal Medicine):
- •Informed consent obtained before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol).
- •Male or female, age above or equal to 18 years at the time of signing informed consent.
- •Is a physician
- •Lives in UK, France, Germany, Italy or Spain
- •Primary medical specialty is:
- •5.a. General Physician/Family Practitioner or Endocrinology or 5.b. Internal Medicine without subspecialty in Hepatology
- •In practice at least 3 years
- •Spends less than 50 percent of their time in an office/clinic setting
- •Spends less than 60 percent of their time in direct patient care
- •Sees at least 15 patients/month with suspected/diagnosed MASH/MASLD
- •Sees and actively treats at least 30 patients/month with Type 2 Diabetes (T2D) and/or Obesity
排除标准
- •Previous participation in this study. Participation is defined as having given informed consent in this study
- •Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation
- •Does not meet inclusion criteria requirements
结局指标
主要结局
Unaided awareness
时间窗: At the time of survey response (Day 1)
Open ended response
Behaviours relative to diagnosing and managing MASLD
时间窗: At the time of survey response (Day 1)
Numerical, multi-select from defined list
Use of current guidelines
时间窗: At the time of survey response (Day 1)
Multi-select from defined list; Likert scales; Numerical Likert scales: 1=Not at all Relevant, 7=Extremely Relevant
Aided awareness
时间窗: At the time of survey response (Day 1)
Multi- select from defined list
Barriers in guideline adoption
时间窗: At the time of survey response (Day 1)
Multi-select from defined list; Likert scales; Numerical Likert scales: 1=Doesn't impact at all, 7=Greatly impacts
次要结局
未报告次要终点